Nearly half of participants in a weight loss program who initiated an antiobesity medication and who consumed alcohol ...

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update NeuroBo Becomes MetaVia On November 18, 2024, NeuroBo Pharmaceuticals ...

The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Brand companies who own GLP-1 products have been pushing the Food and Drug Administration (FDA) to limit their compounding. On August 28, 2024, ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.

About one-third of U.S. adults without diabetes who are eligible for weight loss treatment with glucagon-like peptide 1 (GLP-1) receptor agonists and GLP-1/glucose-dependent insulinotropic polypeptide ...

Defiance ETFs introduces NVOX, a leveraged ETF offering 2X exposure to Novo Nordisk's stock price movements, targeting the ...

Presentations at the 2024 Asembia Specialty Pharmacy Summit focused on reshaping specialty pharmacy while keeping patients ...

While surgery has a low risk for complications, when they do occur, they are serious. This may explain why only 5%-10% of ...

In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...

poll finding that one in eight adult Americans has taken a Glucagon-like peptide-1 (GLP-1), the technical name for ...